

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 29, 2022

Reference is made to the circular of JW (Cayman) Therapeutics Co. Ltd (the “**Company**”) dated June 6, 2022 (the “**Circular**”) incorporating, amongst others, the notice (the “**Notice**”) of annual general meeting of the Company (the “**AGM**”). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Circular.

At the AGM held on June 29, 2022, all the proposed ordinary and special resolutions as set out in the Notice were taken by poll.

As at the date of the AGM, the total number of issued shares of the Company was 410,606,944 Shares, which was the total number of Shares entitling the holders to attend and vote for or against the resolutions proposed at the AGM. There was no restriction on any Shareholder casting votes on any of the proposed resolutions at the AGM. There was no Share entitling the Shareholders to attend and vote only against the proposed resolutions at the AGM. No party has stated its intention in the Circular that it would vote against any proposed resolution or that it would abstain from voting at the AGM.

The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited was appointed as the scrutineer at the AGM for the purpose of vote-taking. The poll results in respect of the respective resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company for the year ended December 31, 2021 and the reports of the directors and auditor thereon.	155,697,580 100.000000%	0 0.000000%
2(a).	(i) To re-elect Ms. Xing Gao as a non-executive director of the Company.	151,835,472 99.505332%	754,815 0.494668%
	(ii) To re-elect Mr. Chi Shing Li as an independent non-executive director of the Company.	152,240,350 99.722634%	423,437 0.277366%
	(iii) To re-elect Mr. Yiu Leung Andy Cheung as an independent non-executive director of the Company.	155,697,580 100.000000%	0 0.000000%
2(b).	To authorise the board of directors of the Company (the "Board") to fix the remuneration of the directors of the Company (the "Directors").	155,697,580 100.000000%	0 0.000000%
3.	To re-appoint PricewaterhouseCoopers as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending December 31, 2022.	155,697,580 100.000000%	0 0.000000%
4(A).	To give a general mandate to the Directors to offer, allot, issue and deal with additional shares in the Company not exceeding 20% of the total number of issued shares of the Company.	145,877,278 93.692707%	9,820,302 6.307293%
4(B).	To give a general mandate to the Directors to repurchase shares in the Company not exceeding 10% of the total number of issued shares of the Company.	141,570,080 90.926320%	14,127,500 9.073680%
4(C).	To extend the general mandate granted to the Directors to allot, issue and deal with shares by the number of shares repurchased by the Company.	131,749,778 84.619027%	23,947,802 15.380973%

SPECIAL RESOLUTION		Number of votes cast and approximate percentage of total number of votes cast	
		For	Against
5.	To approve the adoption of amended and restated memorandum and articles of association of the Company, which contain the proposed amendments to the existing seventh amended and restated memorandum and articles of association of the Company currently in effect as set out in Appendix III of the circular of the Company dated June 6, 2022, in substitution for and to the exclusion of, the existing seventh amended and restated memorandum and articles of association of the Company with immediate effect.	155,117,945 99.627717%	579,635 0.372283%

All Directors have attended the AGM.

Please refer to the Notice for the full text of the resolutions.

As more than 50% of votes were cast in favour of each of the resolutions numbered 1 to 4 above, all of the above ordinary resolutions were duly passed at the AGM. As more than 75% of votes were cast in favour of the resolution numbered 5 above, the above special resolution was duly passed at the AGM.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Yiping James Li
Chairman

Shanghai, PRC, June 29, 2022

As at the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive Director; Dr. Krishnan Viswanadhan, Ms. Xing Gao, Dr. Ann Li Lee, Mr. Jinyin Wang, Dr. Cheng Liu as non-executive Directors, and Mr. Chi Shing Li, Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho as independent non-executive Directors.

* *For identification purpose only*